Emmecell announced in a press release the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to EO2002, the company’s lead investigational magnetic human corneal endothelial cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

EO2002 is an investigational allogeneic-cultured human corneal endothelial cell therapy utilizing Emmecell’s proprietary Magnetic Cell Delivery platform. According to the company, the technology is designed to enhance the localization and retention of therapeutic cells following administration, and the therapy is intended to restore corneal endothelial function without the need for donor tissue transplantation or invasive endothelial keratoplasty.

RMAT designation is intended to expedite the development and review of regenerative medicine therapies for serious conditions when clinical evidence demonstrates the potential to address an unmet medical need. The designation provides opportunities for early and frequent interactions with the FDA, helping to accelerate clinical development, manufacturing discussions, and regulatory review. OM